Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Merck
Fish and Richardson
Baxter
Healthtrust
Accenture
Johnson and Johnson
Julphar
McKinsey

Generated: December 16, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ESKALITH CR

« Back to Dashboard

Clinical Trials for Eskalith Cr

Trial ID Title Status Sponsor Phase Summary
NCT00057681 Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents Completed National Institute of Mental Health (NIMH) Phase 3 This study will evaluate the effectiveness of the medications, lithium (Eskalith®), valproate (Depakote®), and risperidone (Risperdal®) in treating children and adolescents with bipolar disorder or symptoms of mania.
NCT00057681 Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents Completed Washington University School of Medicine Phase 3 This study will evaluate the effectiveness of the medications, lithium (Eskalith®), valproate (Depakote®), and risperidone (Risperdal®) in treating children and adolescents with bipolar disorder or symptoms of mania.
NCT00221975 Combination Therapy in Dual Diagnosis Bipolar Rapid Cycling Completed University Hospitals Cleveland Medical Center Phase 3 Combination Therapy in Dual Diagnosis Bipolar Rapid Cycling: This study recruits males and females age 18 and older who currently meet diagnostic criteria for rapid cycling bipolar disorder (type I or II) and who have met the criteria for substance abuse or dependence of cocaine, marijuana and/or alcohol within the past six months. Patients begin treatment with a combination of lithium and divalproex. Once these medications are tolerated, they are randomly assigned to double-blind treatment with lamotrigine or placebo. Patients remain in this study until they experience a marked bimodal response for four consecutive weeks. This study is sponsored by the Stanley Foundation.
NCT00601575 Bioequivalency Study of 450 mg Lithium Carbonate Under Fed Conditions Completed Roxane Laboratories N/A The objective of this study was to assess the bioequivalence of two Roxane lithium carbonate 450 mg extended release tablet formulations compared to GlaxoSmithKline's Eskalith CR 450 mg extended release tablet under fed conditions using a single-dose, randomized, three-treatment, three-period, six-sequence crossover design.
NCT00602381 Bioequivalency Study of 450 mg Lithium Carbonate Under Fasting Conditions Completed Roxane Laboratories N/A The objective of this study was to assess the bioequivalence of two Roxane lithium carbonate 450 mg extended release tablet formulations compared to GlaxoSmithKline's Eskalith CR 450 mg extended release tablet under fasting conditions using a single-dose, randomized, three-treatment, three-period, six-sequence crossover design.
NCT00627887 Randomised Controlled Trial of Electroconvulsive Therapy (ECT) in Relapse Prevention of Depression Completed Uppsala-Örebro Regional Research Council Phase 4 The purpose of the study is to determine if continuation electroconvulsive therapy (ECT) is safe and effective in relapse prevention of depression.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Eskalith Cr

Condition Name

Condition Name for Eskalith Cr
Intervention Trials
Bipolar Disorder 6
Bipolar Affective Disorder 1
Treatment Resistant Depression 1
Major Depressive Disorder 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Eskalith Cr
Intervention Trials
Bipolar Disorder 7
Disease 2
Depressive Disorder, Major 2
Depressive Disorder 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Eskalith Cr

Trials by Country

Trials by Country for Eskalith Cr
Location Trials
United States 22
Sweden 2
Canada 2
Norway 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Eskalith Cr
Location Trials
Ohio 3
Pennsylvania 3
California 2
Arkansas 2
Missouri 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Eskalith Cr

Clinical Trial Phase

Clinical Trial Phase for Eskalith Cr
Clinical Trial Phase Trials
Phase 4 4
Phase 3 2
N/A 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Eskalith Cr
Clinical Trial Phase Trials
Completed 6
Not yet recruiting 1
Terminated 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Eskalith Cr

Sponsor Name

Sponsor Name for Eskalith Cr
Sponsor Trials
Roxane Laboratories 2
University Hospitals Cleveland Medical Center 2
Washington University School of Medicine 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Eskalith Cr
Sponsor Trials
Other 9
Industry 2
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Healthtrust
UBS
McKinsey
Deloitte
Fuji
Medtronic
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.